Drugs / bivalent OPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02291263 Comparator | Oct 2014 → Jul 2015 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivalent OPV | “The licensing and availability of bivalent OPV (bOPV) containing type 1 and 3 offers the option of an OPV that does not contain OPV2.” NCT02291263 ↗ |
| Known as | bOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02291263 ↗ |
| Modality | Vaccine | “Oral poliovirus vaccines are live attenuated viral vaccines” NCT02291263 ↗ |
| Route | Oral | “Oral poliovirus vaccines are live attenuated viral vaccines” NCT02291263 ↗ |